Methodologic guidelines for the design of high-dose chemotherapy regimens.
about
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.
P2860
Methodologic guidelines for the design of high-dose chemotherapy regimens.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@ast
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@en
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@nl
type
label
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@ast
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@en
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@nl
prefLabel
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@ast
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@en
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@nl
P2093
P1476
Methodologic guidelines for the design of high-dose chemotherapy regimens.
@en
P2093
Doroshow JH
Longmate J
Margolin K
P304
P356
10.1016/S1083-8791(01)80009-4
P577
2001-01-01T00:00:00Z